NCT04454398WITHDRAWNanonymous

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19

Sponsor

Source record

Sorrento Therapeutics, Inc.

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

COVI-GUARD, Standard of Care, Placebo

Indication / condition

AI-normalized

Covid-19

Intervention

Source record

COVI-GUARD, Standard of Care, Placebo

Source & freshness

Source record

NCT ID

NCT04454398

Original source

ClinicalTrials.gov

Source last updated

Jan 08, 2021

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04454398

Title

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19

Sponsor

Sorrento Therapeutics, Inc.

Status

WITHDRAWN

Phase

PHASE1

Condition raw

Covid-19

Condition normalized

Covid-19

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

COVI-GUARD, Standard of Care, Placebo

Target normalized

COVI-GUARD, Standard of Care, Placebo

Interventions

COVI-GUARD, Standard of Care, Placebo

Public preview

Source record

Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of a Single Dose of STI-1499 (COVI-GUARD™) in Hospitalized Patients With Moderate COVID-19

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04454398

Status

WITHDRAWN

Phase

PHASE1

Sponsor

Sorrento Therapeutics, Inc.

Executive brief

Investment-Ready Snapshot

Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARD™) in hospitalized patients with moderate COVID-19

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJan 08, 2021

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04454398

Indication

Covid-19

Modality

monoclonal antibody

Target

COVI-GUARD, Standard of Care, Placebo

Intervention

COVI-GUARD, Standard of Care, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.